Loading...

Home
ETF
COCP

COCP

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

COCP News

Cocrystal Receives FDA Fast Track Designation for CDI-988

Apr 02 2026stocktwits

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988

Apr 02 2026Newsfilter

Cocrystal Pharma Reports FY 2025 Earnings Results

Mar 31 2026seekingalpha

Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026

Dec 18 2025Globenewswire

Cocrystal Pharma to Present Clinical Progress at NobleCon 21

Dec 01 2025Globenewswire

Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies

Oct 02 2025Newsfilter

Cocrystal Pharma reveals direct offering of up to $13 million.

Sep 12 2025SeekingAlpha

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29 2025Newsfilter

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15 2025Newsfilter

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 24 2025Newsfilter

COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More

Apr 01 2025NASDAQ.COM

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31 2025Newsfilter

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Mar 14 2025Globenewswire

Life Sciences Investor Forum Agenda Announced for March 13th

Mar 12 2025Globenewswire

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31 2024Benzinga

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31 2024Benzinga